Kunihiko MIYAZAKI, Hiroaki SATOH, Morio OHTSUKA, Tetsushi ANO, Kensuke NAZAKAWA

Late fatal recurrence in gefitinib-treated NSCLC patients

Gefitinib kanser hücrelerinin çoğalması ve sağkalımlarını kontrol eden signal iletim yolaklarını durduran selektif epidermal büyüme faktörü reseptör tirozin kinaz inhibitörüdür. Gefitinib ile tedavi edilen metastatik küçük hücreli dışı akciğer kanserli hastalarda uzun dönem sağkalım kısa bir süre önce bildirilmiştir. Gefitinib ile uzun süreli hastalık kontrolü sağlandıktan sonra nüks sonrası hızlı bir şekilde ölümcül seyreden iki olguyu sunuyoruz. Gefitinib ile tedavi edilen ölümcül agresif nükslerin biyolojisi yeterli olarak tanımlanmamıştır. Mekanizmadan bağımsız olarak, gefitinib tedavisi uygulayan doktorların bu ilaçla uzun süreli hastalık kontrolünün sağlanmasının ardından ölümcül hızlı nüks olasılığı hakkında dikkatli olmaları gerekmektedir.

Gefitinib ile tedavi edilen küçük hücreli dışı akciğer kanserli hastalarda geç ölümcül nüks

Gefitinib is a selective epidermal growth factor receptor tyrosine kinase inhibitor, which blocks signal transduction pathways implicated in proliferation and survival of cancer cells. Long-term survival in patients with metastatic non-small-cell lung carcinoma (NSCLC) treated with gefitinib has recently been reported. We showed herein two cases of fatal rapid recurrence after a long-term disease control by gefitinib. The biology of fatal aggressive recurrence of gefitinib-treated NSCLC is not well characterized. Regardless of the mechanism, however, physicians treating patients with gefitinib should be alert to the possibility of fatal rapid recurrence after a long-term disease control by this drug.

PDF

___

1. Birnbaum A, Ready N. Gefitinib therapy for non-small cell lung cancer. Curr Treat Options Oncol 2005; 6: 75-81.
2. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs anctivity in human cancer cells by ZD-1839(Iressa), an epidermoid growth factorreceptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6: 2053-63.
3. Magne N, Fischel JL, Dubreuil A, et al. Influence of epidermal growth factor receptor(EGFR), p53 and intrinsic MAP kinase pathway status of tumor cells on the antiproliferative effect of ZD1839(‘Iressa’). Br J Cancer 2002; 86: 1518-23.
4. Nakatomi K, Soda H, Kitazaki T, et al. Long-term survival in three patients with metastatic non-small cell lung cancer treated with gefitinib. Lung Cancer 2006; 52: 253-5.
5. Matsuyama W, Yamamoto M, Machida K, et al. Two lung adenocarcinoma patients with multiple brain metastasis treated with gefitinib and surviving more than 2 years. Nihon Kokyuki Gakkai Zasshi 2006; 44: 653-8 (in Japanese).
6. Kurata T, Tamura K, Kaneda H, et al. Effect of re-treatment with gefitinib(‘Iressa’, ZD1839) after acquisition of resistance. Ann Oncol 2004; 15: 173-7.
7. Yano S, Nakatani E, Ohtsuka S, et al. Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: A report of three cases. Oncol Res 2005; 15: 107-11.
8. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Medicine 2005; 2: 225-35.
9. Greulich H, Chen TH, Feng W, et al. Oncogenic transformation by inhibitor-sensitive and-resistant EGFR mutants. PLoS Medicine 2005; 2: 1167-76.
10. Lewinski T, Zulawski M. Small cell lung cancer survival: 3 years as a minimum for predicting a favorable outcome. Lung Cancer 2003; 40: 203-13.
11. Zelenetz AD, Hamlin P, Kewalramani T, Yahalom J, Nimer S, Moskowitz CH. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin’s lymphoma. Ann Oncol 2003; 14(Suppl 1): 5-10.
12. Linker CA. Autologous stem cell transplantation for acute myeloid leukemia. Bone Marrow Transplant 2003; 31: 731-8.